PNEUMOCOCCAL INFECTION

This study tested a new vaccine called Pn-MAPS30plus to see if it is safe and helps the body fight pneumonia-causing bacteria. It involved 127 healthy adults aged 50 to 64. The vaccine is designed to protect against more types of the bacteria than current vaccines.

This phase 3 trial tested a 13-valent pneumococcal vaccine (13vPnC) against the older 7-valent version in over 1,600 healthy infants in China. The goal was to see if the newer vaccine triggers a stronger immune response and is just as safe. Infants received four doses starting at…

This study tested a new vaccine called V116 in 882 children and teenagers aged 2 to 17 who have a higher risk of pneumococcal disease due to conditions like diabetes or chronic lung disease. The goal was to see if V116 is as good as or better than the current vaccine PPSV23 at tr…

This completed Phase 3 study tested a new vaccine called V116 in 518 adults aged 18 to 64 who are at increased risk for pneumococcal disease due to conditions like diabetes or chronic lung disease. The vaccine targets 21 strains of the bacteria that cause pneumonia and other infe…